Crossmark

Preoperative chemotherapy and carbon ions therapy for treatment of resectable and borderline resectable pancreatic adenocarcinoma: a prospective, phase II, multicentre, single-arm study

Crossref DOI link: https://doi.org/10.1186/s12885-019-6108-0

Published Online: 2019-09-14

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Vitolo, Viviana

Cobianchi, Lorenzo

Brugnatelli, Silvia

Barcellini, Amelia

Peloso, Andrea

Facoetti, Angelica

Vanoli, Alessandro

Delfanti, Sara

Preda, Lorenzo

Molinelli, Silvia

Klersy, Catherine

Fossati, Piero

Orecchia, Roberto

Valvo, Francesca
License Information

Text and Data Mining valid from 2019-09-14

Version of Record valid from 2019-09-14
More Information

Article History

Received: 17 May 2019

Accepted: 29 August 2019

First Online: 14 September 2019

Ethics approval and consent to participate

: The treatment protocol for the current study was reviewed and approved by the local Pavia Ethics Committee. Throughout the trial period, Declaration of Helsinki will be strictly followed in order to guarantee the right of the study subjects. All patients signed an informed consent form before the initiation of therapy. Findings deriving from this study could provide high-quality data on the role of carbon ions therapy in the treatment of pancreatic adenocarcinoma.

: Not applicable

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below